Hone

Hone Health (Hone) is an online clinic providing preventative and proactive longevity care to men and women, delivered through telemedicine. Its care model begins with laboratory testing of biomarkers — the company's site cites more than 50 biomarkers across hormones, heart, brain, liver, kidney, immunity, metabolism and nutrients, while 2025 press coverage and founder interviews reference 40+ and 40 to 100+ biomarkers — followed by a telehealth consultation with a licensed physician, a personalized treatment plan, and shipment of medications and supplements to the patient's home, with retesting and follow-ups to adjust protocols.

Clinical areas span testosterone replacement therapy, menopause and hormone replacement therapy, thyroid conditions, sexual health, weight loss, hair loss (including finasteride and minoxidil), cognitive and energy complaints, and prevention of chronic conditions such as diabetes and cardiovascular disease. Following its January 2025 acquisition of ivee, Hone added in-home healthcare services in which physicians and practitioners deliver care at patients' homes. The company states that its patient engine and proprietary electronic medical record have assembled a large data set on hormones, which it intends to extend into menopause, thyroid and longevity care.

Hone was founded in 2020. It operates a membership model: a Basic tier at $25 per month including biomarker testing every six months, discounted medications and optional paid physician consults, and a Premium tier at $155 per month including testing, telehealth consults, personalized protocols and quarterly retesting; medication costs are additional. An introductory offer prices a biomarker test plus consult at $65. Press coverage in early 2025 described plans starting at $129 per month, with the founder citing $129–$149 per month plus medications.

Founding story

Founder and CEO Saad Alam started the company after his own health decline in his mid-to-late 30s — fatigue, weight gain, loss of focus and stamina, and low mood — for which he spent about a year in the healthcare system without a clear answer before hormone optimization physicians diagnosed clinically low testosterone. The death of his father from chronic diseases he viewed as preventable reinforced the decision, and he concluded that hormonal imbalance affected both men and women and that the existing system was fragmented between bloodwork and treatment providers. Alam has said an early challenge was educating investors and the public at a time when low testosterone was not widely regarded as a medical condition.

Business model

Subscription memberships for telehealth care, with medication and supplement costs charged separately. Public tiers are Hone Basic at $25 per month (biannual testing of 50+ biomarkers, member pricing on medications and supplements, consults purchasable separately) and Hone Premium at $155 per month (testing, telehealth consults, personalized hormone, estrogen and weight-loss protocols, and retesting plus follow-ups every 90 days). An entry offer bundles lab testing of 50+ biomarkers with a physician consult and plan for $65. In a January 2025 interview the CEO described the model as $129 to $149 per month plus the cost of medications.

Recurring monthly membership fees plus revenue from prescribed medications and supplements; in-home care services were added through the ivee acquisition.

Traction

As of January 2025 the company reported crossing 300,000 patients tested and 50,000–55,000 patients treated (figures differ between reports), and stated that 95% of patients choose the Premium membership tier. Management cited customer payback periods roughly half those of other large direct-to-consumer companies and retention two to three times that of other telehealth companies, and said the business was run without excessive venture funding.

Latest developments

In January 2025 Hone Health announced a $33M Series A with participation from Tribe Capital, PIF, Republic Capital, Vibe VC, Humbition, Hanwha, Gaingels, Looking Glass Capital, FJ Labs and Agent Capital plus numerous angels, bringing total funding to $39M, and used the financing to acquire ivee and launch in-home healthcare services. The company said it would expand into broader proactive and preventative longevity care for men and women, invest in clinical trials measuring efficacy, and build out AI-driven longitudinal analysis of lab data. Founder Saad Alam was an Ernst & Young Entrepreneur of the Year finalist in 2024.